Racing Toward Relief: How One Biotech’s New Drug Targets a Genetic Skin Crisis

When life-threatening pustules suddenly erupt across the body accompanied by systemic inflammation, generalized pustular psoriasis (GPP) patients face a medical crisis with few treatment options. As reported by PharmaBiz.com, Vanda…

Continue Reading Racing Toward Relief: How One Biotech’s New Drug Targets a Genetic Skin Crisis
Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
source: shutterstock.com

Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)

Just about one month ago, clinical-stage biotechnology company AnaptysBio announced the availability of positive top-line results from two Phase 3 clinical studies: GEMINI-1 and GEMINI-2. Both studies sought to assess…

Continue Reading Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
Experimental Treatment Could be Potential Breakthrough for Generalized Pustular Psoriasis
jarmoluk / Pixabay

Experimental Treatment Could be Potential Breakthrough for Generalized Pustular Psoriasis

According to a story from dubainewstoday.blogspot.com, the data from a Phase I clinical trial suggests that an experimental drug candidate from the pharmaceutical company Boehringer Ingelheim could substantially improve the…

Continue Reading Experimental Treatment Could be Potential Breakthrough for Generalized Pustular Psoriasis